In silico guided design of non-covalent inhibitors of DprE1: synthesis and biological evaluation

ABSTRACT

DprE1 is a potential target of resistant tuberculosis (TB), especially multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. 2-benzoxazolinone is a closely related bioisostere of some scaffolds such as benzoxazoles, benzimidazole, benzothiazolinone, and benzothiazoles that have been previously explored against DprE1. Thus, a ligand-based quantitative pharmacophore model (AHRR.8) of DprE1 was developed and this pharmacophore model was utilized in activity profiling of some 2-benzoxazolinones from an in-house database using virtual screening. Obtained hits were subject to molecular docking, molecular dynamics (MD), and MM/GBSA calculations, which resulted in benzoyl-substituted derivatives of 2-benzoxazolinone showing strong interactions with the key amino acid residues in the active site of DprE1. Based on in silico results, the top five hits were duly synthesized and evaluated against the XDR-TB strain. This study is an initial effort to explore 2-benzoxazolinones against XDR-TB, which can be submitted further to lead optimization for refining the results.

KEYWORDS:

• DprE1
• pharmacophore modelling
• molecular dynamics
• XDR-TB
• 2-benzoxazolinone

Acknowledgements

H. Verma would like to acknowledge the Indian Council of Medical Research (ICMR), New Delhi for awarding SRF; Award No. ISRM/11(09)/2019.

Disclosure statement

No potential conflict of interest was reported by the authors.

Supplementary material

Supplementary data for this article can be accessed at: https://doi.org/10.1080/1062936X.2021.1900390.